Growth Hormone and IGF-1 Axis

Understanding the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis is critical for grasping how the body regulates growth and metabolism. This neuroendocrine system not only dictates childhood height but also exerts profound influences on body composition, blood sugar, and tissue repair throughout life. For the MCAT and clinical practice, mastering this axis provides a foundational model for endocrine regulation, feedback loops, and the pathophysiology behind conditions like gigantism and acromegaly.

Hypothalamic-Pituitary Regulation: The On/Off Switches

The secretion of growth hormone (GH) is meticulously controlled by the hypothalamus through two primary hormones with opposing actions. Growth hormone-releasing hormone (GHRH) stimulates the anterior pituitary gland’s somatotroph cells to synthesize and release GH. Conversely, somatostatin (also known as growth hormone-inhibiting hormone, GHIH) potently inhibits GH release. This creates a dynamic push-pull system.

Crucially, GH is not secreted at a steady rate; it is released in a pulsatile fashion. You can think of this like a series of waves, with the highest peaks occurring during deep sleep, especially in stages 3 and 4 (slow-wave sleep). This pulsatile pattern is essential for its biological effectiveness. Factors like exercise, stress, and hypoglycemia can trigger a pulse, while hyperglycemia and high levels of circulating IGF-1 suppress it via negative feedback loops to the hypothalamus and pituitary.

GH Signaling: Direct Receptor Binding and Indirect Mediation

Once released into the bloodstream, GH exerts its effects through two primary pathways. First, it can act directly by binding to GH receptors present on target tissues like adipocytes (fat cells) and hepatocytes (liver cells). This direct binding is responsible for many of GH’s metabolic actions.

Its second and most famous pathway is indirect. GH travels to the liver, where it stimulates hepatocytes to produce and release insulin-like growth factor-1 (IGF-1), formerly called somatomedin C. IGF-1 then acts as a classic endocrine hormone, circulating in the blood to mediate GH’s growth-promoting effects on distant tissues, most notably bone and cartilage. This establishes the core axis: Hypothalamus (GHRH/Somatostatin) → Pituitary (GH) → Liver (IGF-1) → Target Tissues.

IGF-1: The Primary Mediator of Linear Growth

While GH has direct metabolic roles, the promotion of longitudinal bone growth is primarily orchestrated by IGF-1. In children and adolescents, the ends of long bones contain epiphyseal plates (growth plates), which are layers of cartilage. Circulating IGF-1 stimulates the proliferation and differentiation of chondrocytes (cartilage cells) within these plates. As chondrocytes multiply, mature, and are eventually replaced by bone, the long bones lengthen, leading to increases in height.

This process requires a permissive hormonal environment, including thyroid hormone and sex steroids (estrogen and testosterone), which eventually promote the closure of the epiphyseal plates in late adolescence. Once these plates fuse, longitudinal growth ceases. This timing is the key differentiator between the disorders of GH excess in children versus adults.

Metabolic Actions: The Anti-Insulin Effects

Beyond growth, GH plays a crucial counter-regulatory role in metabolism, often described as having anti-insulin effects. Its goal is to mobilize energy stores. On adipose tissue, GH increases lipolysis, the breakdown of triglycerides into free fatty acids and glycerol, making fatty acids available for energy production. On glucose metabolism, GH reduces glucose uptake in muscles and promotes glucose production (gluconeogenesis) in the liver, thereby increasing blood glucose levels. These diabetogenic actions are why prolonged, excess GH can lead to insulin resistance and diabetes mellitus.

In contrast, IGF-1 has insulin-like effects, promoting glucose uptake in muscle and fat. The balance between GH’s anti-insulin actions and IGF-1’s pro-insulin actions is a fine-tuned metabolic dance.

Clinical Disorders: Gigantism and Acromegaly

Disorders of the GH/IGF-1 axis vividly illustrate its physiological principles. Excess GH is almost always caused by a benign pituitary adenoma of somatotroph cells.

If this excess occurs before epiphyseal plate closure in a child, it results in gigantism. This is characterized by excessive and proportional linear growth, leading to very tall stature. All bones lengthen, resulting in true giantism.

If the excess begins after epiphyseal plate closure in an adult, it causes acromegaly. Since long bones can no longer lengthen, growth occurs in tissues that remain responsive: membranous bones and soft tissues. Classic signs include coarse facial features (enlarged nose, lips, and jaw), prognathism (protruding jaw), enlarged hands and feet (patients often report increasing ring or shoe size), and organomegaly (enlarged heart, tongue, liver). The metabolic effects are also prominent, with hypertension, diabetes, and joint arthritis being common complications.

Diagnosis involves finding elevated IGF-1 levels (a stable marker of overall GH secretion) and failure to suppress GH during an oral glucose tolerance test. Treatment aims to remove or shrink the tumor via surgery or radiation and to normalize hormone levels with medications like somatostatin analogs or a GH receptor antagonist.

Common Pitfalls

1. Confusing Direct vs. Indirect Effects: A common MCAT trap is attributing all of GH’s actions to IGF-1. Remember: lipolysis and anti-insulin effects are primarily direct actions of GH on adipose and liver tissue. Linear bone growth is the classic indirect effect mediated by IGF-1.
2. Misunderstanding Pulsatile Secretion: It is incorrect to state that GH levels are always elevated in conditions of excess. While the baseline between pulses is higher and the pulses are more frequent, secretion is still pulsatile. This is why a random GH level is unreliable for diagnosis; clinicians measure the more stable downstream product, IGF-1.
3. Misidentifying the Disorder by Timing: Simply associating "too much GH" with "gigantism" is a mistake. You must connect the timing to plate closure. Gigantism = open plates. Acromegaly = closed plates. A patient diagnosed at age 30 with coarse features has acromegaly, even if the tumor likely started growing in their late teens.
4. Overlooking Metabolic Complications: When thinking about GH excess, don't focus solely on physical appearance. The insulin resistance, diabetes, hypertension, and cardiomegaly (enlarged heart) are major causes of morbidity and mortality in acromegaly and are key management points.

Summary

• The growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis is centrally regulated by hypothalamic GHRH (stimulatory) and somatostatin (inhibitory), resulting in the pulsatile secretion of GH, primarily during deep sleep.
• GH promotes longitudinal bone growth indirectly by stimulating the liver to produce IGF-1, which then drives chondrocyte proliferation in the epiphyseal plates.
• GH exerts important direct metabolic actions, including increasing lipolysis and blood glucose, giving it overall anti-insulin effects.
• Excess GH causes gigantism in children (before epiphyseal plate closure) and acromegaly in adults (after plate closure), with the latter featuring growth of membranous bones and soft tissues.
• Diagnosis hinges on elevated IGF-1 levels and a non-suppressible GH, while management focuses on tumor control and normalization of the hormonal axis.